Fritextsökning
Artiklar per år
Innehållstyper
-
Tirzepatide approved for obesity by the FDA – to be branded as Zepbound
Diabetes drug tirzepatide has now also been approved in the US for treating obesity.
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic have achieved just that, and they are thus making a significant contribution to the history of Swedish medicine. He is now being awarded the Research!Sweden Award 2023.
-
High-tech companies are increasingly focusing on health
Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more about them advancing their positions,” says Anna Lefevre Skjöldebrand, CEO of Swedish Medtech.
-
Årets patientföreträdare utsedd på konferens
Under måndagen utsågs Årets Patientföreträdare 2022 på konferensen Fokus Patient. Priset gick i år till Föreningen för Hörselskadade och Döva barn med familjer.
-
Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”
With mixed emotions, Charlotta Gummeson will leave her position as CEO of Sahlgrenska Science Park in October. “It feels sad and exciting at the same time. I’ve been in the thick of things and part of the development for so long now, but I’m also looking forward and thinking about all the new things that there will be in a freer role,” she says to Life Science Sweden
-
Elon Musks hjärnchip får grönt ljus för att testas på människor
Ett implantat som ska göra det möjligt att styra datorer med tankens kraft. Nu har Elon Musks Neuralink fått klartecken för kliniska studier med sitt hjärnchip på människor – och söker försökspersoner.
-
19 medicines in Sweden are under investigation in a major EMA inquiry
19 medicines marketed in Sweden are affected by an ongoing extensive European investigation into suspected fraud at an Indian contract research organisation. Among them are medicines for HIV, epilepsy, cancer and Parkinson’s, which may be withdrawn unless new evidence can be provided that they are up to standard.
-
The Swedish government is to increase its investment in cancer care
The Swedish government wants to invest more in cancer and paediatric cancer care and proposes to allocate SEK 500 million per year for this purpose in the coming years.
-
Bioarctic granted Japanese patent for Parkinson’s disease candidate
Bioarctic has been granted a Japanese patent for its antibodies targeting Parkinson’s disease.
-
Small robots to deliver pharmaceuticals to the body
Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list that aims to promote sustainable entrepreneurship.
-
Lucy Robertshaw: Artificial intelligence – is this really going to transform a patient’s life?
In a column Lucy Robertshaw reflects on how AI and new regulations will affect healthcare, innovation and the lives of future patients.
-
Novo Nordisk invests billions in expanding its production capacity
Danish pharmaceutical company Novo Nordisk is making a major investment to develop and expand its production facility in Hillerød, north of Copenhagen. DKK 15.9 billion, equivalent to almost SEK 25 billion, is being invested over six years.
-
Study: Semaglutide tablet produces weight loss
The pharmaceutical semaglutide is effective for weight loss even when given in tablet form, according to a phase 3 study.
-
Looking for greater Nordic cooperation – “We have Norway and Finland in our sights”
How can Medicon Valley Alliance bring the big pharmaceutical companies back to the organisation? Life Science Sweden discussed this topic and others with the cluster organisation’s new radar pair.
-
Conference on Alzheimer’s reveals several advances in the field
In Gothenburg, Sweden, researchers and pharmaceutical companies from all over the world gathered to discuss one specific issue – neurological diseases. Life Science Sweden has talked to some of those that attended the conference.
-
How critical are the “Spermageddon” reports? – Researchers call for action
A much talked about meta-study indicates that sperm concentration in men’s seminal fluid has halved in 40 years. Experts in andrology that Life Science Sweden speaks to believe that the results must be taken seriously, and call for action from the Swedish authorities.
-
Column: ”Life as a F1 race”
"The F1 car makes several pit stops during a race and during a lifetime the human being may also have to come in several times for maintenance", Björn Ursing writes in a column.
-
Fjärrprogrammerad behandling för patienter med nervsmärta
Behandling av neuropatisk smärta i hjärna och ryggmärg kan nu följas upp och omprogrammeras på distans vid Akademiska sjukhuset i Uppsala.
-
Column: ”We need to exploit the benefits of the regulations“
You don’t need to search long on the Internet to find lists of the most innovative countries with Sweden ranking at the top. Sweden generally offers good conditions for growing new solutions, but it is also becoming increasingly clear that we are challenged in one area – regulations, writes Björn Arvidsson in a column.
-
Gynnsamma fas I-data för Active Biotechs ögondroppar
Lundbaserade Active Biotech rapporterar positiva resultat från en klinisk fas I-studie som testar säkerhet och tolerabilitet hos den nyutvecklade ögondroppsformuleringen av laquinimod i friska försökspersoner.
-
"Unclear proposal from the EU Commission on how to solve the MDR challenges"
Even before the EU regulation on medical devices (MDR) came into force, medical technology companies and doctors were concerned that it would endanger the availability of medical devices in the EU. Unfortunately, the fears have come true.
-
”Otydligt förslag från EU-kommissionen om hur MDR-utmaningarna ska lösas”
Redan innan EU-förordningen om medicintekniska produkter (MDR) trädde i kraft fanns en oro hos medicinteknikföretag och läkare för att den skulle äventyra tillgången på medicintekniska produkter i EU. Farhågorna har dessvärre besannats.
-
Ny app visar hur synskadade upplever världen
En ny app visar hur allt från grå starr till makuladegeneration och ålderssynthet yttrar sig — ur den synskadades synvinkel. Syftet är att ge seende en inblick i hur personer med synnedsättning uppfattar sin vardag.
-
Medtech-företag blev årets snabbväxare
Medtech-bolaget Infosolutions toppar årets rankning från Deloitte över Sveriges snabbast växande teknikbolag. På fyra år har bolaget ökat sin omsättning med 12 815 (!) procent.
BREAKING